TY - JOUR
T1 - Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles
AU - Scarberry, Kenneth E.
AU - Dickerson, Erin B.
AU - Zhang, Z. John
AU - Benigno, Benedict B.
AU - McDonald, John F.
N1 - Funding Information:
The research was supported by grants from The Ovarian Cycle Foundation, The Deborah Nash Harris Endowment, and the Ovarian Cancer Institute.
PY - 2010/6
Y1 - 2010/6
N2 - A majority of ovarian cancer metastases result from the shedding of malignant cells from the primary tumor into the abdominal cavity. Free-floating cancer cells in serous effusions of late-stage ovarian cancer patients may spread to internal organs, making effective treatment extremely difficult. Selective removal of ovarian cancer cells from serous fluids may abate metastasis and improve long-term prognoses. We have already shown that superparamagnetic nanoparticles conjugated to an ephrin-A1 mimetic peptide with a high affinity for the EphA2 receptor can be used to capture and remove cultured human ovarian cancer cells from the peritonea of experimental mice. Here we demonstrate the potential clinical utility of the methodology by in vitro capture and isolation of cancer cells from the ascites fluid of ovarian cancer patients. From the Clinical Editor: Ovarian cancer metastases usually are the result of shedding of malignant cells from the primary tumor into the abdominal cavity. In this paper, a novel nanotechnology-based method is demonstrated for the in vitro capture and isolation of cancer cells from the ascites fluid of ovarian cancer patients.
AB - A majority of ovarian cancer metastases result from the shedding of malignant cells from the primary tumor into the abdominal cavity. Free-floating cancer cells in serous effusions of late-stage ovarian cancer patients may spread to internal organs, making effective treatment extremely difficult. Selective removal of ovarian cancer cells from serous fluids may abate metastasis and improve long-term prognoses. We have already shown that superparamagnetic nanoparticles conjugated to an ephrin-A1 mimetic peptide with a high affinity for the EphA2 receptor can be used to capture and remove cultured human ovarian cancer cells from the peritonea of experimental mice. Here we demonstrate the potential clinical utility of the methodology by in vitro capture and isolation of cancer cells from the ascites fluid of ovarian cancer patients. From the Clinical Editor: Ovarian cancer metastases usually are the result of shedding of malignant cells from the primary tumor into the abdominal cavity. In this paper, a novel nanotechnology-based method is demonstrated for the in vitro capture and isolation of cancer cells from the ascites fluid of ovarian cancer patients.
KW - Magnetic nanoparticles
KW - Metastatic cancer therapy
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=77952744087&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952744087&partnerID=8YFLogxK
U2 - 10.1016/j.nano.2009.11.003
DO - 10.1016/j.nano.2009.11.003
M3 - Article
C2 - 19969103
AN - SCOPUS:77952744087
SN - 1549-9634
VL - 6
SP - 399
EP - 408
JO - Nanomedicine: Nanotechnology, Biology, and Medicine
JF - Nanomedicine: Nanotechnology, Biology, and Medicine
IS - 3
ER -
